10
The programmed cell death protein 1 (PD-1) limits effector 11
T-cell functions in peripheral tissues, and its inhibition leads 12 to clinical benefit in different cancers. To better understand how 13 PD-1 blockade therapy modulates the tumor-host interactions, 14
we evaluated three syngeneic murine tumor models, the 15 BRAF
V600E
-driven YUMM1.1 and YUMM2.1 melanomas, and 16 the carcinogen-induced murine colon adenocarcinoma 17
MC38. The YUMM cell lines were established from mice with 18 melanocyte-specific BRAF V600E mutation and PTEN loss 19 (BRAF
/PTEN À/À ). Anti-PD-1 or anti-PD-L1 therapy engen-20 dered strong antitumor activity against MC38 and YUMM2.1, but 21 not YUMM1.1. PD-L1 expression did not differ between the three 22 models at baseline or upon interferon stimulation. Whereas 24 mutational load was high in MC38, it was lower in both YUMM 25 models. In YUMM2.1, the antitumor activity of PD-1 blockade 26 had a critical requirement for both CD4 and CD8 T cells, as well as 27 CD28 and CD80/86 costimulation, with an increase in CD11c gies (1) (2) (3) (4) . Tumor responses are associated with a higher number 44 of pretreatment PD-L1-expressing tumor and myeloid cells (5, 6), 45 a high mutational load leading to increase in antigen-specific 47 T-cell recognition (7, 8) , the ability of PD-1/PD-L1 blockade to 48 increase antigen presentation (9, 10) and modulate the tumor 49 microenvironment (10, 11), and pre-existing CD8 T-cell infiltra-50 tion (5, 12). A higher tumor mutational load induced by carcino-51 gens such as ultraviolet light for melanoma (13) or cigarette 52 smoking for lung carcinomas (14) would allow T cells to better 53 differentiate between cancer and normal cells, thereby leading to 54 immune recognition that could be unleashed by PD-1 blockade 55 therapy.
56 Despite these advances, a better understanding is needed of the 57 tumor-host interactions and how anti-PD-1 agents modulate 58 cellular and molecular characteristics of each individual micro-59 environment. It is widely accepted that PD-1 blockade agents 60 regulate T-cell activity in peripheral tissues in the context of 61 infection or in tumors where PD-1/L1 checkpoint is the dominant 62 inhibitory pathway. However, anti-PD-1 interacts earlier with T 63 cells positively regulated by B7-CD28 costimulation (15), and 64 this interaction is less well characterized (16) (17) (18) .
65 In this study, we analyzed different tumor-host characteristics 66 that might influence the effects of PD-1 blockade in murine models 67 with a fully functional immune system. We conclude that T-cell 68 priming and costimulation are required for anti-PD-1 therapy 69 response to be effective in the melanoma tumor models in vivo.
70

Materials and Methods
71
Mice, cell lines, and reagents 72 C57BL/6 mice, B6.Cg-Braftm1MmcmPtentm1HwuTg(Tyr-cre/ 73 ERT2)13Bos/BosJ, B6.129S2-Cd28tm1Mak/J, and B6.129S4- 
Results
227
In vivo syngeneic animal models with differential responses to 228 PD-1 pathway blockade 229
In order to have animal models that consistently respond to 230 anti-PD-1 therapy, we tested four melanoma models, three 231 derived from BRAF V600E /PTEN À/À genetically engineered mice 232 (Supplementary Fig. S1A ) and B16, and compared them with 233 MC38, a cell line that has been previously shown to respond well 234 to PD-1 blockade therapy (30, 31) . In three replicate studies, we 235 observed antitumor activity of anti-PD-1 or anti-PD-L1 antibody 236 therapy against MC38 (Fig. 1A ) and YUMM2.1 (Fig. 1B) , but no 237 antitumor activity against YUMM1.1 ( Fig. 1C) , YUMM1.7, or B16 238 ( Supplementary Fig. S1B ). Of note, these responses to anti-PD-1 239 antibody are incomplete, and both MC38 and YUMM2.1 tumors 240 start regrowing around days 35 to 40 after tumor injection. We 241 decided to focus our further mechanistic studies in MC38 for a 242 tumor that is known to respond to anti-PD-1, and studied the 243 differential responses in YUMM1.1 and YUMM2.1.
244
Similar PD-L1 expression induced in MC38, YUMM2.1, and 245
YUMM1.1 by IFNg 246
In order to investigate the mechanism of response to anti-PD-1 247 therapy, we first focused on induced PD-L1 expression in these 248 three cell lines. Total cellular PD-L1 increased upon exposure to 249
IFNg in the three cell lines, with a higher magnitude of increase in 250 MC38 cells than in YUMM2.1 and YUMM1.1 cells ( Fig. 2A ).
252 Surface expression of PD-L1 was low at baseline, and increased 253 upon exposure to IFNg in the three cell lines, though less evident 254 in the morphologically more heterogeneous YUMM1.1 cell line 255 (Fig. 2B ).
256
Increased mutational load in MC38 compared with YUMM1.1 257 and YUMM2.1 258 Next, we determined whether mutational load is a contributor 259 to the observed differential response to anti-PD-1 therapy. MC38, 260 which was established from a mouse exposed to the carcinogen 261 dimethylhydralazine (32), has a higher mutational load (2,778 262 mutations), compared with the much lower mutational rates in 263 YUMM1.1 and YUMM2.1 (128 and 68 nonsynonymous variants, 264 respectively; Supplementary Fig. S1C ). Despite independent der-265 ivation, 26 variants are shared by YUMM1.1 and YUMM2.1, 266 which likely represent SNPs not found in the sequenced strain-267 matched control or in the National Center for Biotechnology Information database of genetic variation. Copy-number varia-271 tion analysis revealed substantial differences in chromosomal 272 alteration patterns between the three cell lines (Fig. 2C) . However, 273 most are shallow amplifications or deletions (log 2 ratio between 274 0.5 and 1.5).
275
CD8 and CD4 T cells important in response to PD-1 blockade in 276 MC38 and YUMM2.1 277
To elucidate the role of CD8 and CD4 T cells in anti-PD-1 278 activity, both cell subtypes were depleted in C57BL/6 mice bear-279 ing MC38 or YUMM2.1 tumors. Antibody-mediated depletion 280 was confirmed in YUMM2.1 tumors and spleens (Supplementary 281 Fig. S2A and S2B ). In the absence of CD8 cells, CD4 cells, or both, 282
antitumor response diminished in both MC38 and YUMM2.1 283 models ( Fig. 3A and B) . Of note, CD8 cell depletion (anti-PD-284 1aCD8) in the YUMM2.1 tumor model only partially abrogated 285 the response to anti-PD-1 therapy, whereas CD4 cell depletion, or 286 CD4 plus CD8 depletion, completely abrogated this response 287 (Fig. 3B ).
288
Increased TILs in MC38, but decreased in YUMM2.1, upon PD-1 289 blockade 290
Three and ten days after starting treatment with anti-PD-1 or 291 isotype control, tumors and spleens were harvested and stained 292 for CD3, CD4, and CD8 ( Supplementary Fig. S2C and S2D ). CD8 293 T-cell infiltration increased in MC38 tumors (calculated as per-294
centage of all cells in the tumor) on day 3 and day 10 of treatment 295 with anti-PD-1 when compared with isotype control (Fig. 3C ), 296 whereas CD8 T cells in the corresponding spleens of MC38 297 tumor-bearing mice remained unchanged ( Supplementary Fig.  298 S2E). No significant difference in the percentage of CD4 T cells was 299 observed in MC38 tumors (Fig. 3C ) and spleens (Supplementary 300 Fig. S2F ). However, CD8 T-cell infiltration into YUMM2.1 tumors 301 was significantly decreased on day 10 of anti-PD-1 therapy when 302 compared with isotype control. This decrease in CD8 T cells was 303 not present on day 3 (anti-PD-1 d3) compared with isotype 304 control group (Fig. 3D ). CD8 T cells did not decrease in the 305 corresponding spleens of any of the conditions in the YUMM2.1 306 model ( Supplementary Fig. S2E ). The percentage of CD4 T cells in 307 the YUMM2.1 tumors or spleens was not significantly different 308 across different time points or between anti-PD-1 and isotype 309 control tumors (Fig. 3D) . The YUMM1.1 tumor model did not 310
show any CD8 T-cell variation in either tumors or spleens com-311 paring anti-PD-1 and isotype control-treated conditions (Sup-312
plementary Fig. S2G ). When we calculated the absolute number of 313 CD8 T cells per gram of tumor pooled from two separate experi-314 ments, it confirmed the significant increase in CD8 T cells in the 315 MC38 tumors (Fig. 3E ) and the significant decrease in CD8 T cells 316 in the YUMM2.1 tumors on day 10 of anti-PD-1 treatment (Fig.  317  3F) . Immunofluorescence staining of tumors and spleens from 318 mice in the YUMM2.1 group collected after anti-PD-1 therapy or 319 isotype control also demonstrated a remarkable decrease in intra-320 tumoral CD8 T cells on day 10 and no change in spleen (Fig. 3G) .
322 Wnt/b-catenin uninvolved in YUMM2.1 CD8 T-cell decrease or 323 response to anti-PD-1 324 YUMM2.1 cell line was derived from a mouse with the same 325 genetic background as YUMM1.1 but containing an additional 326 transgenic allele that, when recombined by tamoxifen induction, 327 produces a stabilized b-catenin, which leads to increased meta-328 static potential of the tumors (33) . However, whole-exome 329 sequencing and PCR showed that b-catenin was unrecombined 330 in the YUMM2.1 cell line, and the recombination could be 331 induced by tamoxifen (4HT; Supplementary Fig. S3A and S3B) . Supplementary Fig. S3C ) and in macro-dissected tumor sections 335 when implanted in mice (Supplementary Fig. S3D ) (Fig. 4A) . Knockdown of 341 b-catenin in YUMM2.1 did not change the significant decrease of 342 CD8 T cells on day 10 with anti-PD-1 treatment when compared 343 with the respective isotype-treated controls ( Fig. 4B and C) .
344 Silencing b-catenin did not change the antitumor response in the 345 YUMM2.1 model (Fig. 4D) , nor did it change in the nonrespon-346 sive YUMM1.1 model (Fig. 4E) . Fig. S4A and S4B ). The percentage of CD11c þ 370
B220
-cells was significantly decreased in MC38 tumors of mice 371 treated with anti-PD-1 compared with isotype control, with no 372 significant change in YUMM2.1 or YUMM1.1 tumors (Fig. 5C ). (Fig. 5D) . Growth of tumors in 380 mice that were CD103-depleted was analogous to nondepleted 381 mice, with or without the addition of anti-PD-1 (Fig. 5E ). Of note, 382
anti-PD-1-treated YUMM2.1 tumors exhibited a significant 383 increase in CD11c
DCs compared with isotype control-treated tumors (Fig. 5F ).
385
This finding was not present in MC38 tumors. Supplementary Fig. S4D ). Anti-PD-1 did not change 414 the percentage of MO-MDSCs or PMN-MDSC in any 415 tumors compared with isotype control (Fig. 6C) . Another immune-suppressive cell population, regulatory T cells (T regs ; 419
Supplementary Fig. S4E ;
, showed a 420 nonstatistically significant trends toward a decrease in MC38 and 421 YUMM2.1 tumors with anti-PD-1 and an increase in YUMM1.1 422 (Fig. 6D) . Representative flow charts of TAMs, MDSCs, and T regs 423 are shown in Fig. 6E .
424
A more inflammatory gene signature profile in YUMM2.1 425 compared with YUMM 1.1 426 RNA was extracted from cultured YUMM1.1 and YUMM2.1 and 427 subjected to RNA sequencing. GSEA and pathway analyses indi-428 cated that immune response, cytokine production, and inflam-429 matory-related genes were strongly represented in YUMM2.1 430 compared with YUMM ¼ 1.1 cells (Fig. 7A) . Corresponding 431 normalized enrichment scores (NES), P values, and FDR of the 432 GSEA plots are included (Fig. 7B) . Analysis of genes that code for 433 secreted proteins with a log 2 -fold higher than 1 in YUMM2.1 434 compared with YUMM1.1 cells revealed an increase in inflam-435 matory and chemotaxis-related genes ( Supplementary Fig. S4F ).
436 Discussion 558 When looking into the ability of the models to evoke an 559 inflammatory reaction required for immune cell recruitment and 560 DC-T-cell costimulation, YUMM2.1 exhibited an "inflammatory 561 profile" consistent with an endogenous upregulation of immune, 562 cytokine producing, and inflammatory response-related genes. 563 The YUMM2.1 model could therefore intrinsically harbor inflam-564 matory mediators necessary to couple innate recognition to 565 T-cell-mediated immunity by DCs in vivo, which is also supported 566 by the increase in chemotactic factors such as Cxcl10, Ccl6, or 567 Cxcl12. This observation is consistent with other reports, where 568 chemokine-trafficking of immune cells into tumors was observed 569 in human melanoma cell lines (49) or in mice receiving adoptive 570 cell therapy and anti-PD-1 blockade (50) . 571 In conclusion, T-cell priming supports anti-PD-1 antitumor 572 responses mediated by CD4 and CD8 T cells, critically requiring 573 costimulation in vivo. 
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